Lilly sells Actos sales rights to Takeda-WEB ONLY

Eli Lilly and Co. has sold the rights to sell the diabetes drug Actos in seven countries to Takeda Pharmaceutical Co., Asia’s biggest drugmaker, Bloomberg News reported this morning.

Takeda will sell Actos in Canada, Belgium, Denmark, Norway, Sweden and Turkey, a company spokesman told Bloomberg yesterday.

Terms of the deal were not disclosed.

Takeda developed Actos in the late 1990s, but has relied on Indianapolis-based Lilly to market the drug in those markets.

The Japan-based company already sells the drug itself in the United States, Britain and France.

Financial daily Nikkei said Actos had sales of $3.2 billion in the Americas alone in the fiscal year ended March 31, 2008.

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our updated comment policy that will govern how comments are moderated.

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets on
{{ count_down }}